Browse studies

Find your next paid study

90 recruiting studies matching your filters

A Randomized Phase II Study of Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab in Participants With Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

This phase II Expanded Lung-MAP treatment trial compares how well sacituzumab govitecan alone, ivonescimab alone, or sacituzumab govitecan in combination with …

Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Estimated

~$75 – $3,000

Actual pay is set by the research site.

SWOG Cancer Research NetworkNCT07393555

Phase 3

A Phase III Randomized Clinical Trial of Proton Craniospinal Irradiation Versus Involved-Field Radiotherapy for Patients With Breast Cancer or Non-Small Cell Lung Cancer Leptomeningeal Metastasis (Radiate-LM)

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell l…

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Lung Non-Small Cell Carcinoma+2 more

Estimated

~$50 – $2,250

Actual pay is set by the research site.

NRG OncologyNCT06500481

Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix

This study collects information and data on patients with neuroendocrine cervical cancer. Information from this study may be used to better understand the corr…

Cervical Large Cell Neuroendocrine CarcinomaCervical Neuroendocrine CarcinomaCervical Small Cell Carcinoma+19 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer

A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targ…

Non-Small Cell Carcinoma of Lung, TNM Stage 4Non-Small Cell Lung CancerEGFR Gene Mutation+3 more

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Colorado, DenverNCT03042221

Experiences With and Attitudes Towards Immune Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer (NSCLC) - A Single Center, Survey-Based Study

This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immuno…

Lung Non-Small Cell Carcinoma

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Southern CaliforniaNCT07339254

Phase 2

Phase II Study of Diclofenac Salvage in Patients Metastatic Non-Small Cell Lung Cancer With Early Signs of Progression on Single Agent PD(L)-1 Blockade

This phase II trial tests how well diclofenac works in treating patients non-small cell lung cancer (NSCLC) that may have spread from where it first started (p…

Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+1 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Emory UniversityNCT06731270

Phase 2

A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small…

Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Estimated

~$75 – $3,000

Actual pay is set by the research site.

SWOG Cancer Research NetworkNCT05642572

Phase 2

A Phase II Trial of GT103 in Combination With Pembrolizumab in STK11 Mutant Non-Small Cell Lung Cancer (NSCLC)

This phase II trial tests how well GT103 in combination with pembrolizumab works in treating patients with STK11 mutant non-small cell lung cancer that may hav…

Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+1 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Roswell Park Cancer InstituteNCT07017829

Observational

A Single-Arm Phase II Study of Personalized Dose Guidance for Stereotactic Body Radiotherapy (SBRT) in Patients With Lung Tumors

This phase II trial tests the effectiveness and safety of artificial intelligence (AI) to determine dose recommendation during stereotactic body radiation ther…

Lung CarcinomaLung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the Lung+3 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Northwestern UniversityNCT05802186

Observational

The Impact of Surgical Technique on Circulating Tumor DNA in Early-Stage Non-Small Cell Lung Cancer

This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor…

Lung Non-Small Cell CarcinomaStage I Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Thomas Jefferson UniversityNCT05502523

Phase 1

(TESSERACT): Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TBI)

This phase I/II trial studies the side effects, safety, and effectiveness of low dose radiation to the entire body (total body irradiation \[TBI\]) and higher …

Extensive Stage Lung Small Cell CarcinomaStage IV Lung Cancer

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Vanderbilt-Ingram Cancer CenterNCT06110572

Observational

LiveWellLung: A Prehabilitation Intervention Program to Promote Resiliency and Operative Success Among Adults Receiving Lung Cancer Surgery (ROAR-LCS) With Biospecimen Collection

This clinical trial tests two different physical therapy and relaxation interventions, one in-person and at-home called Resiliency and Operative Success for Ad…

Resectable Lung Non-Small Cell Carcinoma

Estimated

~$10 – $750

Actual pay is set by the research site.

Ohio State University Comprehensive Cancer CenterNCT07584239